Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.

Purpose: External validation of existing risk calculators (RC) to assess the individualized risk of detecting prostate cancer (PCa) in prostate biopsies is needed to determine their clinical usefulness. The objective was to externally validate the Rotterdam Prostate Cancer RCs 3 and 4 (RPCRC-3/4) and that incorporating PHI (RPCRC-PHI) in a contemporary Spanish cohort.

Methods: Multicenter prospective study that included patients suspicious of harboring PCa.

Do PHI and PHI density improve detection of clinically significant prostate cancer only in the PSA gray zone?

Objectives: Prostate health index (PHI) is a predictive biomarker of positive prostate biopsy. The majority of evidence refers to its use in the PSA gray zone (4-10 ng/mL) and negative digital rectal exam (DRE). We aim to evaluate and compare the predictive accuracy of PHI and PHI density (PHId) with PSA, percentage of free PSA and PSA density, in a wider range of patients for the detection of clinically significant prostate cancer (csPCa).

Lack of transferability between different immunoassays and LC-MS/MS for total 25-hydroxyvitamin D measurement and disagreement defining deficiency.

Background: Over the last few years, it has become much more common to measure concentrations of vitamin D, as its deficiency has been associated with an increasing number of health problems. Recently, a number of new immunoassays for measurement of total 25-hydroxyvitamin D (25OH-D) concentration have been released but their results may not be transferable.

Methods: Our main objective was to compare results from the Cobas(®) e411 (Roche Diagnostics), Advia Centaur(®) (Siemens), Architect (Abbott), IDS-iSYS (Vitro S.